[FLXN] Flexion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.71 Change: 2.14 (11.52%)
Ext. hours: Change: 0 (0%)

chart FLXN

Refresh chart

Strongest Trends Summary For FLXN

FLXN is in the medium-term down -18% below S&P in 4 months and down -39% below S&P in 1 year. In the long-term down -61% below S&P in 2 years and down -63% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.24% ROE-21.88% ROI
Current Ratio32.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.69 M Cash From Investing Activities-62.47 M Cash From Operating Activities-9.98 M Gross Profit
Net Profit-9.17 M Operating Profit-9.01 M Total Assets141.02 M Total Current Assets134.24 M
Total Current Liabilities4.16 M Total Debt Total Liabilities4.19 M Total Revenue
Technical Data
High 52 week23.96 Low 52 week9.07 Last close11.2 Last change6.87%
RSI55.5 Average true range0.76 Beta1.4 Volume629.96 K
Simple moving average 20 days9.76% Simple moving average 50 days2.72% Simple moving average 200 days-11.76%
Performance Data
Performance Week23.48% Performance Month2.75% Performance Quart-10.83% Performance Half-18.19%
Performance Year-52.28% Performance Year-to-date-1.06% Volatility daily4.51% Volatility weekly10.1%
Volatility monthly20.69% Volatility yearly71.67% Relative Volume286.22% Average Volume569.03 K
New High New Low

News

2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

2019-09-10 07:36:12 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

2019-09-09 16:01:00 | Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

2019-09-06 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-04 09:55:01 | Flexion Therapeutics, Inc. FLXN Shares March Higher, Can It Continue?

2019-09-04 08:23:35 | Need To Know: Flexion Therapeutics, Inc. NASDAQ:FLXN Insiders Have Been Buying Shares

2019-09-03 14:21:23 | In expense-laden biotech industry, here are the Mass. startups most in need of cash

2019-08-28 16:30:00 | Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

2019-08-10 12:01:00 | 3 Healthcare Stocks With Rising Expectations

2019-08-07 17:45:05 | Edited Transcript of FLXN earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-07 16:26:02 | Flexion Therapeutics, Inc. FLXN Q2 2019 Earnings Call Transcript

2019-08-06 18:35:10 | Flexion Therapeutics FLXN Reports Q2 Loss, Tops Revenue Estimates

2019-08-06 16:01:00 | Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights

2019-08-05 08:53:30 | How Should Investors Feel About Flexion Therapeutics, Inc.'s NASDAQ:FLXN CEO Pay?

2019-08-02 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-07-30 16:30:00 | Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019

2019-07-30 10:38:02 | Will Flexion Therapeutics FLXN Report Negative Q2 Earnings? What You Should Know

2019-07-15 07:30:00 | Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in Patients with Advanced Knee OA

2019-07-05 06:47:42 | Flexion Therapeutics, Inc. NASDAQ:FLXN: When Will It Breakeven?

2019-07-03 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-24 13:28:10 | Here’s What Hedge Funds Think About Flexion Therapeutics Inc FLXN

2019-06-20 09:00:00 | Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year

2019-06-18 16:30:00 | Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

2019-06-07 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-05 08:30:00 | Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis

2019-05-30 06:58:51 | If You Had Bought Flexion Therapeutics NASDAQ:FLXN Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today

2019-05-20 12:48:46 | These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month

2019-05-14 16:30:00 | Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

2019-05-12 21:50:08 | Here’s What Hedge Funds Think About Flexion Therapeutics Inc FLXN

2019-05-10 13:06:21 | Flexion Therapeutics, Inc. FLXN Q1 2019 Earnings Call Transcript

2019-05-10 07:30:00 | Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® triamcinolone acetonide extended-release injectable suspension

2019-05-09 11:58:00 | Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today

2019-05-09 09:45:38 | Chevron, Conduent, Flexion, and More: Stocks in the Spotlight

2019-05-09 01:34:59 | Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 18:35:10 | Flexion Therapeutics FLXN Reports Q1 Loss, Lags Revenue Estimates

2019-05-08 17:25:58 | Flexion Therapeutics: 1Q Earnings Snapshot

2019-05-08 16:01:00 | Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights

2019-05-08 14:30:00 | Flexion Therapeutics, Inc. to Host Earnings Call

2019-05-03 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-02 09:00:00 | Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International OARSI World Congress

2019-05-01 16:30:00 | Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019

2019-04-25 07:58:40 | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

2019-04-24 16:30:00 | Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension

2019-04-23 12:53:34 | Flexion Therapeutics, Inc. NASDAQ:FLXN: Time For A Financial Health Check

2019-04-05 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-04-03 16:30:00 | Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference

2019-04-02 07:30:00 | Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in the Journal Drugs

2019-04-01 09:00:00 | Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board

2019-03-11 08:00:07 | Mutual Fund Managers Are Bullish On Stock Market Forecast — But Some Are Hedging Bets

2019-03-04 16:30:00 | Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference